Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01793181|
Recruitment Status : Completed
First Posted : February 15, 2013
Last Update Posted : November 25, 2016
Retinal vein occlusion (RVO) is a common vascular disease of the eye. Studies have shown that the risk of venous thrombosis is higher in winter so even concerning RVO. Studies have shown a possible link between sun exposure and venous thrombosis. Vitamin D levels have been shown to have a similar seasonal variation, with a peak occurring in the summer. The primary source of vitamin D is from sunlight when ultraviolet B (UVB) radiation penetrates the skin and converts 7-dehydrocholesterol to 25-hydroxycholecalciferol vitamin D3 (25-OHVitD) via previtamin D. In Stockholm situated at latitude 59˚ 20΄ North, it is not possible to synthesize vitamin D at sufficient levels in winter and the exposure time required to reach a standard dose is impractical from at least October through March.
The aim of the study is to evaluate vitamin D levels in central retinal vein occlusion (CRVO) patients and compare them with the vitamin D levels in randomly selected control patients matched for age and month of disease onset. This is to evaluate whether vitamin D deficiency may be a risk factor in the onset of CRVO.
The hypothesis of the study is that patients with CRVO have lower levels of vitamin d than matched controls.
|Condition or disease|
|Vitamin d Deficiency Central Retinal Vein Occlusion|
|Study Type :||Observational|
|Actual Enrollment :||216 participants|
|Official Title:||Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||November 2014|
Patients with a newly diagnosed CRVO. Maximum duration 3 months.
Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
- Vitamin D levels [ Time Frame: one year ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01793181
|St Eriks Eye Hospital|
|Stockholm, Sweden, 11282|